Research On The Performance Of Digital Transformation In Pharmaceutical Enterprises

With the development of the digital economy,a variety of digital technologies have emerged in the market,in order to promote the digital transformation of all walks of life,the state issued a series of relevant documents to support,coupled with recent years,the demographic structure has undergone tremendous changes,the broad masses of the people’s awareness of health management has been further improved,and China’s pharmaceutical market demand has grown significantly.Promoting the digital transformation of pharmaceutical enterprises is the only way to improve enterprise production efficiency and reduce costs,and it is also a necessary measure for China to build a digital power.However,for most pharmaceutical companies,there are still problems of unclear transformation paths and unclear impact on corporate performance.Based on the above background,this paper selects CR Sanjiu,a large state-controlled listed company,as a research case,to provide reference for the digital transformation of pharmaceutical enterprises by exploring the motivation and path of its digital transformation,and then uses the entropy-mutation series method to establish a performance evaluation system for the digital transformation of CR Sanjiu,and analyzes the effect of CR Sanjiu’s digital transformation from four dimensions:financial performance,business performance,social performance and innovation performance.It is found that:first,the performance evaluation system constructed by the entropy-mutation series method in this paper is universal for the majority of pharmaceutical enterprises,so it can provide a reference for the performance evaluation of digital transformation of pharmaceutical enterprises.Second,digital transformation has a certain positive impact on enterprise performance,but it will not cause large fluctuations in enterprise performance,and it has a short lag,and usually achieves better performance growth in the year after the implementation of the initiative.Third,CR 39’s digital transformation has a good effect,which is a reference for the path of digital transformation of pharmaceutical enterprises;Fourth,CR Sanjiu had problems such as high sales expenses and insufficient short-term solvency during the digital transformation.Combined with the analysis of case studies,this paper concludes that pharmaceutical companies should pay attention to their own development trends in the process of digital transformation and establish digital transformation programs based on industry characteristics,in general,digital transformation is an integrated process,simply introducing digital technology is difficult to help enterprises improve performance,only to create a collaborative manufacturing platform,achieve data interconnection,and comprehensively build a digital system,in order to truly reduce production costs and improve operational efficiency with digital transformation.Specifically,digital transformation can be comprehensively implemented from multiple links such as R&D,production,operation management,marketing and circulation,and user services.By exploring the motivation and path in the digital transformation process of CR Sanjiu and the change trend of enterprise performance before and after digital transformation,this paper not only supplements the lack of research on the impact of digital transformation on enterprise performance in the pharmaceutical industry,but also enriches the application of mutation progression method in enterprise performance research,and provides reference for the digital transformation of other pharmaceutical enterprises in the same industry.